Microbiome Profiling in Bladder Cancer Patients Using the First-morning Urine Sample

Nardelli, Carmela; Aveta, Achille; Pandolfo, Savio Domenico; Tripodi, Lorella; Russo, Filippo; Imbimbo, Ciro; Castaldo, Giuseppe; Pastore, Lucio

doi:10.1016/j.euros.2023.11.003

Cited by 20 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, EAU guidelines also report, among risk factors for more aggressive cancer, patients’ related characteristics, such as ethnicity, with African-American patients having worse outcomes, advancing age, tobacco consumption, delayed surgery, high comorbidity and performance indices scores, and several blood-based biomarkers even if no prognostic biomarkers are validated for clinical use (LE: 3) [ 43 , 44 , 45 , 46 , 47 ]. These latter characteristics are mentioned in the AUA/SUO, but the panel considers them to be not widely available, easily identified, or measured, thereby limiting broad applicability.…”

Section: Resultsmentioning

confidence: 99%

Upper Tract Urothelial Cancer: Guideline of Guidelines

Pandolfo,

Cilio,

Aveta

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Upper tract urothelial carcinoma (UTUC) is a rare disease with a potentially dismal prognosis. We systematically compared international guidelines on UTUC to analyze similitudes and differences among them. Methods: We conducted a search on MEDLINE/PubMed for guidelines related to UTUC from 2010 to the present. In addition, we manually explored the websites of urological and oncological societies and journals to identify pertinent guidelines. We also assessed recommendations from the International Bladder Cancer Network, the Canadian Urological Association, the European Society for Medical Oncology, and the International Consultation on Bladder Cancer, considering their expertise and experience in the field. Results: Among all the sources, only the American Urologist Association (AUA), European Association of Urology (EAU), and the National Comprehensive Cancer Network (NCCN) guidelines specifically report data on diagnosis, treatment, and follow-up of UTUC. Current analysis reveals several differences between all three sources on diagnostic work-up, patient management, and follow-up. Among all, AUA and EAU guidelines show more detailed indications. Conclusions: Despite the growing incidence of UTUC, only AUA, EAU, and NCCN guidelines deal with this cancer. Our research depicted high variability in reporting recommendations and opinions. In this regard, we encourage further higher-quality research to gain evidence creating higher grade consensus between guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

Upper Tract Urothelial Cancer: Guideline of Guidelines

Pandolfo,

Cilio,

Aveta

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…This lower frequency of genetic alterations in younger patients compared to the general population may be due to the fact that exposure to many urothelial carcinogens from occupational exposure or the direct inhalation of tobacco smoke is restricted to adults and that the time interval between exposure and subsequent carcinogenesis leading to tumor development is several years. Another possible explanation for this lower frequency of mutations in pTERT could be due to a lower or different exposure to microorganisms and their metabolites that may alter the functional state of tissues mediated by chronic inflammation and the immune system and thus contribute to the development of tumors in this group of patients [24,30]. Various studies performed on bladder tumors in a population with a mean age of approximately 65-75 years detected no relationship between sex and rate of pTERT mutations [8,20,27,28].…”

Section: Discussionmentioning

confidence: 99%

Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors

Pérez González,

Heredia-Soto,

Girón de Francisco

et al. 2024

CIMB

View full text Add to dashboard Cite

The TERT (Telomerase Reverse Transcriptase) gene promoter mutation is one of the most prevalent mutations in urothelial bladder tumors and this mutation is related to bladder tumor progression. Our purpose was to evaluate the presence of this mutation in a population of patients who were first diagnosed at age ≤ 40 years and to examine its relationship with tumor characteristics and progression. A molecular study was performed to detect the two most prevalent mutations in the TERT promoter (C228T and C250T). The study included 29 patients, with a mean follow-up of 152 months. There were no statistically significant differences in the clinical or tumor characteristics according to the presence or absence of the mutation. Although the mutation group showed poorer recurrence-free survival (RFS), there was no statistically significant difference and there was no difference in progression-free survival by group (p > 0.05). The pTERT mutations in bladder tumor cells occurred less frequently in younger patients than in older patients, a finding that could indicate different mechanisms of carcinogenesis. The trend towards lower RFS in patients with mutated pTERT needs to be confirmed by further studies, given the small number of patients included in these studies due to the low incidence of bladder tumors in this age group.

show abstract

“…The interest in studying inflammatory-associated biomarkers in BC has increased over the last decade. Studies investigating, for example, the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and the urinary microbiome, have shown promising results as biomarkers for BC [ 6 , 7 , 8 , 9 ]. However, further research identifying other candidate biomarkers is still needed.…”

Section: Introductionmentioning

confidence: 99%

Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients

Vikerfors,

Davidsson,

Carlsson

et al. 2024

IJMS

View full text Add to dashboard Cite

Urinary bladder cancer (BC) represents a major health issue, and identifying novel biomarkers for early disease detection and outcome prediction is paramount. It has already been established that the immune system plays a role in tumour initiation and progression in which the inflammatory marker pentraxin 3 (PTX3) might be involved, presenting a variety of functions in different cancers. The aim of this study was to investigate whether plasma levels of PTX3 could be used as a biomarker for patients with BC. Plasma levels of PTX3 were determined in 118 BC patients and 50 controls by ELISA. Patients with BC had significantly higher PTX3 levels compared to controls. The value as a diagnostic biomarker is probably limited, however, since no significant difference in PTX3 levels was seen between patients with non-muscle-invasive BC and controls; they were seen only between patients with muscle-invasive disease and controls. However, the potential value of PTX3 as a prognostic biomarker was indicated by significantly higher PTX3 levels in patients who developed metastatic disease during follow-up compared to patients who did not develop metastatic disease. The conclusions from this study are that plasma levels of PTX3 have limited value as a diagnostic biomarker, although they have potential as a prognostic biomarker for patients with BC.

show abstract

Microbiome Profiling in Bladder Cancer Patients Using the First-morning Urine Sample

Cited by 20 publications

References 30 publications

Upper Tract Urothelial Cancer: Guideline of Guidelines

Upper Tract Urothelial Cancer: Guideline of Guidelines

Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors

Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients

Contact Info

Product

Resources

About